The State of Biologics Testing Report 2026

Why It Matters

The findings give biopharma executives actionable insight into how modern testing approaches can accelerate product timelines while meeting tighter regulatory expectations, directly influencing market competitiveness.

Key Takeaways

• Report documents shift from compendial methods to digital testing platforms
• Regulators encourage animal reduction and risk‑based biologics assessments
• Biotech firms cite faster timelines as key driver for new modalities
• Charles River leverages global testing data to benchmark industry best practices

Pulse Analysis

The biologics landscape is at a crossroads, with developers balancing breakthrough science against the practicalities of testing speed, credibility, and animal welfare. Regulatory bodies worldwide are revising guidance to reward innovative, risk‑based approaches, while investors demand shorter time‑to‑market cycles. This environment forces companies to rethink traditional compendial assays, which often lag behind the rapid evolution of modalities such as gene‑edited proteins, cell therapies, and multispecific antibodies.

Charles River’s 2026 report captures this transition by mapping how leading firms are integrating digital tools—automated data capture, AI‑driven analytics, and cloud‑based workflows—into their testing pipelines. The study reveals a marked increase in the use of in‑silico models and physiologically‑based simulations, reducing reliance on animal studies and aligning with the 3Rs (Replacement, Reduction, Refinement) principles. Risk‑based testing frameworks are gaining traction, allowing organizations to prioritize critical quality attributes and allocate resources more efficiently, ultimately shortening development timelines.

For industry leaders, the report offers a benchmark for measuring progress against peers and identifying gaps in capability. Embracing these advanced testing paradigms can lower costs, improve regulatory compliance, and enhance data integrity, providing a competitive edge in a crowded market. As biologics continue to diversify, firms that adopt digital, risk‑focused testing strategies are poised to accelerate product launches and sustain long‑term growth.